Ménière Disease: Endolymphatic Hydrops
Ménière disease is a disorder of the inner ear characterized by excessive accumulation of endolymph in the membranous labyrinth — a phenomenon called endolymphatic hydrops. This increase in endolymphatic pressure triggers episodic attacks of intense rotatory vertigo (lasting 20 minutes to 12 hours), fluctuating hearing loss, and ipsilateral tinnitus — the classic triad that defines the disease.
The disease affects about 50 to 200 people per 100,000 population, with a peak between 40 and 60 years of age and a slight female predominance. The pathophysiology involves an imbalance in the production and reabsorption of endolymph — mediated by autonomic dysfunction of cochlear flow, possible autoimmune component, and triggering factors such as stress, excess sodium, and barometric changes.
Conventional Treatments for Ménière Disease
Conventional treatment of MD aims to reduce the frequency and intensity of attacks and preserve auditory function — with progressive therapeutic escalation from conservative to invasive.
THERAPEUTIC LADDER OF MÉNIÈRE DISEASE
| LEVEL | TREATMENT | MECHANISM | LIMITATION |
|---|---|---|---|
| 1st — General measures | Low-sodium diet (<2g NaCl/day), stress control | Reduction of endolymphatic osmolarity | Variable efficacy; difficult prolonged dietary adherence |
| 2nd — Pharmacologic | Betahistine 48 mg 3x/day (BEMED trial: high dose) | H3 antagonist / cochlear H1 agonist | BEMED trial: no difference vs. placebo in double-blind; GI effects |
| 3rd — Diuretic | Hydrochlorothiazide 12.5–25 mg/day ± triamterene | Reduction of systemic endolymphatic volume | Hypokalemia, hypotension; low-quality evidence |
| 4th — IT corticosteroid injection | Intratympanic dexamethasone (multiple injections) | Anti-inflammatory + local immune modulation | Painful invasive procedure; risk of tympanic perforation |
| 5th — IT gentamicin | Unilateral chemical ablation of the vestibular labyrinth | Eliminates vestibular function of the affected ear | Additional hearing loss in 10%–30%; irreversible |
| 6th — Surgery | Endolymphatic sac decompression / labyrinthectomy | Mechanical reduction of hydrops | Risk of total hearing loss; reserved for severe refractory cases |
How Acupuncture Acts on Endolymphatic Hydrops
Medical acupuncture acts on multiple stages of MD pathophysiology — from autonomic control of cochlear vascularization to modulation of the local inflammatory response.
Mechanisms of Action in Ménière Disease
1. Autonomic Modulation of Cochlear Vascularization
GB-20 and GV-20 reduce sympathetic tone through vagus nerve activation (via the nucleus tractus solitarius). This reduction in cochlear sympathetic activity reverses vasospasm of the stria vascularis — decreasing excessive endolymph production. It is the most relevant mechanism for reducing attack frequency.
2. Neuromodulation of the Vestibulocochlear Nerve (CN VIII)
TJ-17 (Yifeng), positioned on the mastoid posterior to the earlobe, is the reference point of the facial and vestibulocochlear nerves. Its needling produces somatosensory reflex neuromodulation on CN VIII. TJ-21 (Ermen) and GB-2 (Tinghui), pré-tragal, stimulate the anterior auricular plexus — somatosensory reflex to the cochlea.
3. Reduction of Endolymphatic Inflammation
In animal models of endolymphatic hydrops, acupuncture at TJ-21 reduced IL-1β and TNF-α in the perilymphatic and endolymphatic compartments. This local anti-inflammatory effect complements the reduction of hydrodynamic pressure — and may be especially relevant in MD with autoimmune component.
4. Stress Control and HPA Axis
SP-6 and KI-3 modulate the hypothalamic-pituitary-adrenal axis, reducing cortisol secretion — a hormone that amplifies cochlear vasospasm and stress reactivity. Patients with MD have significantly elevated cortisol levels during and between attacks.
5. Treatment of Associated Tinnitus
TJ-3 (Zhongzhu) and GB-43 (Xiaxi) specifically modulate the perception of high-frequency tinnitus through activation of the auditory córtex via the thalamus. ST-36 and SP-6 elevate β-endorphins, which reduce subjective tinnitus intensity. Evidence shows improvement in 60%–70% of cases of tinnitus associated with MD.
Auricular and Periauricular Points
- • TJ-17 — Yifeng: mastoid, CN VII and VIII
- • TJ-21 — Ermen: superior pré-tragal
- • GB-2 — Tinghui: inferior pré-tragal
- • TJ-3 — Zhongzhu: high-frequency tinnitus
- • GB-43 — Xiaxi: distal auditory córtex
Systemic Support Points
- • GB-20 — Fengchi: autonomic + vertebral artery
- • GV-20 — Baihui: vagal activation, cortisol
- • SP-6 — Sanyinjiao: HPA axis, stress
- • KI-3 — Taixi: kidney deficiency (auditory yin)
- • LR-3 — Taichong: Liver Qi imbalance
Scientific Evidence
The Frontiers in Neurology meta-analysis (2022) combined 8 RCTs with 720 patients, comparing acupuncture with betahistine, diuretics, and sham acupuncture.
COMPARATIVE RESULTS — ACUPUNCTURE VS. BETAHISTINE (FRONTIERS IN NEUROLOGY 2022 META-ANALYSIS)
| OUTCOME | ACUPUNCTURE | BETAHISTINE | OBSERVATION |
|---|---|---|---|
| Total DHI (0–100) | −22 pts | −14 pts | Difference described in meta-analysis; quality of evidence heterogeneous |
| Frequency of attacks/month | −67% | −43% | Suggested benefit in Chinese studies; Western replication still limited |
| Mean duration of attacks | −52% | −31% | Secondary finding; small samples |
| Tinnitus VAS (0–10) | −2.4 pts | −1.6 pts | Trend; without robust statistical significance |
| Audiometry (PTA) | No difference | No difference | No treatment modifies lost hearing |
| Tolerability | Rare adverse events | Reported GI effects | Any medication adjustment must be made by the otorhinolaryngologist |
Clinical Protocol for Ménière Disease
Treatment Stages
Initial Evaluation
Recent audiometry and impedance audiometry (rule out otitis, evaluate baseline PTA). Number of attacks/month, baseline DHI. Identified triggering factors (sodium, stress, hormones, barometry). Betahistine in use: assess whether there is real benefit (many patients do not respond — candidates for transition to acupuncture).
Intensive Phase — Weeks 1 to 6
Two sessions/week. Protocol: TJ-17 + TJ-21 + GB-2 (periauricular); GB-20 + GV-20 (autonomic); SP-6 + KI-3 + LR-3 (systemic). Semi-permanent auricular acupuncture (press-tack needles) at the auricular "kidney" and "shen men" points between sessions. Strict low-sodium diet (<2g/day) as a mandatory adjunct measure.
Maintenance Phase — Weeks 7 to 16
One session/week. After stabilization of attacks, reduce to biweekly. Most patients achieve ≥50% reduction in attacks at 8 weeks. Long-term monthly maintenance is recommended for relapse prevention.
Acute Attack Management
Do not perform acupuncture during the intense acute attack (prostrate patient, vomiting). Wait for resolution of the acute phase (usually 20min–12h). In the 48h post-attack, acupuncture helps in the recovery of balance and reduces residual aural fullness. Antihistamine (dimenhydrinate) or antiemetic (ondansetron) can be used in attacks, without interference with acupuncture.
When Medical Acupuncture Is Especially Indicated in Ménière
Priority Indications
- • MD with insufficient response to betahistine (within the ENT plan)
- • GI intolerance to betahistine, as a complementary option
- • Bilateral MD in multidisciplinary discussion about IT gentamicin
- • Intense tinnitus associated with MD
- • MD with predominant stress/anxiety component
- • Pregnant women with MD, as non-pharmacologic support (together with the obstetrician and ENT)
Realistic Expectations
- • Acupuncture reduces attacks but does not cure MD definitively
- • No evidence of improvement in established sensorineural hearing loss
- • Better results in early MD (mild to moderate hearing loss)
- • Adherence to a low-sodium diet is essential for the result
- • Periodic maintenance necessary for relapse prevention
- • Severe refractory cases may require IT gentamicin after failure of acupuncture
Frequently Asked Questions
Frequently Asked Questions
Sensorineural hearing loss established by MD is not reversed by acupuncture — just as it is not reversed by betahistine, diuretics, or any conventional clinical treatment. Acupuncture acts in the fluctuating phase of hearing loss (during and after attacks), and may prevent progressive worsening by reducing the frequency of attacks. Hearing that has been lost permanently (endolymphatic fibrosis) does not recover with any non-surgical treatment.
We do not recommend acupuncture during the intense phase of an attack (vertigo with vomiting, prostration). Wait for the spontaneous resolution of the attack (20 minutes to 12 hours), use antiemetic if necessary. In the 24–48 hours post-attack, acupuncture is excellent for accelerating recovery of balance and relieving residual aural fullness.
They are distinct protocols with different points and objectives. In MD, the focus is autonomic cochlear control (TJ-17, TJ-21, GB-2) and stress modulation (GV-20, SP-6). In cervicogenic vertigo, the focus is suboccipital proprioceptive recalibration (GB-20, BL-10, GV-16, Jiaji C1–C3). Careful diagnostic evaluation by the medical acupuncturist is essential to apply the correct protocol.
Yes. Betahistine, when already prescribed by the otorhinolaryngologist, is maintained while acupuncture is introduced — there is no known pharmacologic interaction between the two approaches. Any decision to reduce or discontinue betahistine is exclusively that of the attending physician, based on clinical evolution; acupuncture should not be used as a pretext for medication adjustment.
Clinical studies show significant reduction in attack frequency after 4–6 weeks of intensive treatment (2 sessions/week). Some patients perceive improvement after the first 3–4 sessions. The response is faster in patients with recent-onset MD (<2 years) than in long-standing cases with established cochlear damage.